Reported signals
abatacept
Registration status unknownDrugalgemeen
135,351
reports (FAERS)
60.5%
reported as serious
8,457
fatal reports (6.2%)
30
signals above threshold
2026-07
last updated
Signal ranking · ROR
What stands out in the reports.
On the labelNew signalUnknown & frequent
Symptom
0.1110100
ROR [95% CI]
Anti-cyclic citrullinated peptide antibody positive
562.7 [531.0–596.2]
Pemphigus
433.4 [416.1–451.5]
Hand deformity
242.2 [233.6–251.1]
Synovitis
226.6 [219.8–233.6]
Contraindicated product administered
150.8 [147.3–154.4]
Glossodynia
94.4 [91.8–97.1]
Pericarditis
85.7 [83.0–88.6]
Systemic lupus erythematosus
59.9 [58.4–61.4]
Wound
53.1 [51.6–54.6]
Rheumatoid arthritis
50.3 [49.5–51.1]
Arthropathy
44.6 [43.6–45.5]
Joint swelling
36.3 [35.7–36.8]
Therapeutic product effect decreased
34.4 [33.5–35.3]
Drug intolerance
26.9 [26.4–27.5]
Treatment failure
22.6 [22.2–23.1]
ROR = reporting odds ratio (log scale). A value above 1 means the symptom is reported more often for this product than for all other products combined. This measures how much it stands out in reports — not cause, not risk.
Interpretation
Summary not yet available — will be auto-generated.
Label versus report
On the label
No signals currently mapped to the label.
Newly reported
Anti-cyclic citrullinated peptide antibody positive
Pemphigus
Hand deformity
Synovitis
Contraindicated product administered
Glossodynia
Pericarditis
Systemic lupus erythematosus
Recall history · 0 on record
No recalls on record.
Compare within ALGEMEEN
Source & citation
HealthProves. abatacept — reported signals. Retrieved 2026-07-05. Source: openFDA (FAERS). healthproves.com/abatacept/
FAERS135,351 records
Retrieved2026-07-05
MethodROR / disproportionality